Thrombosis Medical Journal Abstracts
Advert for Healthcare Professionals only
Safety and Efficacy of Ultra-high-dose, Short-term Thrombolysis with rt-PA for Acute Lower Limb Ischemia
European Journal of Vascular and Endovascular Surgery
May 2013
Safety and Efficacy of Ultra-high-dose, Short-term Thrombolysis with rt-PA for Acute Lower Limb Ischemia
Objectives: The evaluation of success and complication rates of ultra high-dose recombinant tissue plasminogen activator (rt-PA) administered over a short time frame in the treatment of acute lower limb ischemia. Methods: This was a prospective single-center study. The outcome of treatment in 97 patients with acute..25-hydroxyvitamin D concentrations and risk of venous thromboembolism in the general population with 18,791 participants
Journal of Thrombosis and Haemostasis
Dec 2012
25-hydroxyvitamin D concentrations and risk of venous thromboembolism in the general population with 18,791 participants
Background: Vitamin D has potential antithrombotic effects suggesting that vitamin D analogs could be used as adjunctive antithrombotic agents. However, epidemiological evidence of an association between reduced 25-hydroxyvitamin D concentrations and risk of venous thromboembolism is lacking. Objectives: We tested the..Platelet dysfunction associated with the novel Trp29Cys thromboxane A2 receptor variant
Journal of Thrombosis and Haemostasis
Dec 2012
Platelet dysfunction associated with the novel Trp29Cys thromboxane A2 receptor variant
Background: Genetic variations that affect the structure of the thromboxane A2 (TP) receptor provide insights into the function of this key platelet and vascular receptor, but are very rare in unselected populations. Objectives: To determine the functional consequences of the TP receptor Trp29Cys (W29C) substitution...Rituximab for thrombotic thrombocytopenic purpura (TTP): benefit of early administration during acute episodes and use of prophylaxis to prevent relapse
Journal of Thrombosis and Haemostasis
Dec 2012
Rituximab for thrombotic thrombocytopenic purpura (TTP): benefit of early administration during acute episodes and use of prophylaxis to prevent relapse
Background: Rituximab has been documented in the treatment of acute (≤3 days from admission), relapsed/refractory TTP and given as prophylaxis in selected cases to prevent acute relapse. The precise timing of Rituximab in acute TTP has not been determined. Objective: To perform a retrospective analysis of rituximab use..Biochemical and functional characterization of a recombinant monomeric Factor VIII-Fc fusion protein
Journal of Thrombosis and Haemostasis
Dec 2012
Biochemical and functional characterization of a recombinant monomeric Factor VIII-Fc fusion protein
Background: Hemophilia A results from a deficiency in FVIII activity. Current treatment regimens require frequent dosing owing to the short half-life of FVIII. A recombinant FVIII-Fc fusion protein (rFVIIIFc) was molecularly engineered to increase the half-life of FVIII, 1.5–2-fold in several preclinical animal models..Induction of platelet aggregation following direct physical interaction with diesel exhaust particles
Journal of Thrombosis and Haemostasis
Dec 2012
Induction of platelet aggregation following direct physical interaction with diesel exhaust particles
Background: There is a proven link between exposure to traffic-derived particulate air pollution and the incidence of platelet-driven cardiovascular diseases. It is suggested that inhalation of small, nanosized particles increases cardiovascular risk via toxicological and inflammatory processes and translocation of..Platelets express and release osteocalcin and co-localize in human calcified atherosclerotic plaques
Journal of Thrombosis and Haemostasis
Dec 2012
Platelets express and release osteocalcin and co-localize in human calcified atherosclerotic plaques
Background: Although vascular-calcification mechanisms are only partially understood, the role of circulating calcifying cells and non-collagenous bone matrix proteins in the bone-vascular axis is emerging. Despite that platelets represent a cellular interface between hemostasis, inflammation, and atherosclerosis and..The incidence and magnitude of fibrinolytic activation in trauma patients
Journal of Thrombosis and Haemostasis
Nov 2012
The incidence and magnitude of fibrinolytic activation in trauma patients
Background: Trauma is a global disease with over 2.5 million deaths annually from haemorrhage and coagulopathy. Overt hyperfibrinolysis is rare in trauma and associated with massive fatal injuries. Paradoxically, clinical trials suggest a much broader indication for antifibrinolytics. Objective: To determine the..Severe stroke: patient profile and predictors of favourable outcome
Journal of Thrombosis and Haemostasis
Nov 2012
Severe stroke: patient profile and predictors of favourable outcome
Background: Severe stroke carries a high rate of mortality and morbidity. The aims of this study are to determine the characteristics of patients that initially presented with severe ischaemic stroke, and to identify acute and subacute predictors of favourable clinical outcome in these patients. Methodology: An..Platelet Function Normalization after a Prasugrel Loading Dose: Time-dependent Effect of Platelet Supplementation
Journal of Thrombosis and Haemostasis
Nov 2012
Platelet Function Normalization after a Prasugrel Loading Dose: Time-dependent Effect of Platelet Supplementation
Background: Hemostatic benefits of platelet transfusions in thienopyridine-treated acute coronary syndrome (ACS) patients may be compromised by residual metabolite in circulation. Objectives: To estimate the earliest time after a prasugrel loading-dose when added platelets are no longer inhibited by..The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy
Journal of Thrombosis and Haemostasis
Nov 2012
The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy
Background: Oral contraception (OC) and postmenopausal hormone therapy (HT) can be used to alleviate menopausal symptoms. However, the risk of venous thrombosis (VT) associated with OC use in women over 50 years old has never been assessed and the two preparations have not been directly compared. Objectives: To..A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia
Journal of Thrombosis and Haemostasis
Nov 2012
A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia
Background: Drug-induced immune thrombocytopenia (DITP) can be confirmed by the demonstration of drug-dependent platelet antibodies in vitro; however, laboratory testing is not readily accessible and test methods are not standardized. Objective: To identify drugs with the strongest evidence for causing DITP based on..Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty
Thrombosis Research
Jan 2012
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty
Introduction: The RECORD programme compared oral rivaroxaban with enoxaparin for prevention of venous thromboembolism after elective total hip or knee replacement. This analysis compared the safety of concomitant use of specified medications with rivaroxaban and enoxaparin by evaluating postoperative bleeding rates..A Randomized Controlled Trial of Empiric Warfarin Dose Reduction with the Initiation of Doxycycline Therapy
Thrombosis Research
Jan 2012
A Randomized Controlled Trial of Empiric Warfarin Dose Reduction with the Initiation of Doxycycline Therapy
Background: When interacting medications, such as doxycycline, are initiated during warfarin therapy, one method to correct for non-therapeutic international normalized ratio (INR) is adjusting the warfarin dose, if necessary. Another approach is preemptive warfarin dose adjustment. This study's objective was to..Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time
Thrombosis Research
Jan 2012
Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time
Vitamin K antagonists (VKA) are monitored with prothrombin time (PT) based assays that are equally sensitive to reductions in factors II, VII or X. We compared the effect of vitamin K dependent (VKD) coagulation factors on PT and also on rotational thromboelastometric (ROTEM) parameters. The PT was equally sensitive to..Pioglitazone inhibits platelet function and potentiates the effects of aspirin: A prospective observation study
Thrombosis Research
Jan 2012
Pioglitazone inhibits platelet function and potentiates the effects of aspirin: A prospective observation study
Background: Thiazolidinediones (TZDs) are agonists of PPARγ and exert beneficial metabolic effects in patients with diabetes. They may also affect platelet function. Objectives: To characterize potential platelet inhibitory effect of pioglitazone alone and in the presence of aspirin. Methods: 20 normal and 20 diabetic..Genetic modulation of the FVLeiden/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes
Journal of Thrombosis and Haemostasis
Jan 2012
Genetic modulation of the FVLeiden/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes
Background and Objectives: The factor (F) V Leiden mutation causes activated protein C (APC) resistance by decreasing the susceptibility of FVa to APC-mediated inactivation and by impairing the APC-cofactor activity of FV in FVIIIa inactivation. However, APC resistance and the risk of venous thromboembolism (VTE) vary..Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT
Journal of Thrombosis and Haemostasis
Jan 2012
Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT
Background: Early-onset hypertensive disorders (HD) of pregnancy and small-for-gestational age infants (SGA) are associated with placental vascular thrombosis, these often recur and are also associated with inheritable thrombophilia. Aspirin reduces the recurrence risk. Objectives: Adding low-molecular-weight heparin..Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial
Journal of Thrombosis and Haemostasis
Jan 2012
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial
Background: A recombinant factor VIIa analog (NN1731; vatreptacog alfa [activated]) was developed to provide safe, rapid and sustained resolution of bleeds in patients with hemophilia and inhibitors. Patients/Methods: This global, prospective, randomized, double-blinded, active-controlled, dose-escalation trial..Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?
Atherosclerosis
Jan 2012
Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?
Objective: To quantify the circumferential healing process at 6 and 12 months following scaffold implantation. Background: The healing process following stent implantation consists of tissue growing on the top of and in the space between each strut. With the ABSORB bioresorbable vascular scaffold (BVS), the outer..Role for the Guanine Nucleotide Exchange Factor Phosphatidylinositol-3,4,5-Trisphosphate–Dependent Rac Exchanger 1 in Platelet Secretion and Aggregation
Arteriosclerosis, Thrombosis and Vascular Biology
Dec 2011
Role for the Guanine Nucleotide Exchange Factor Phosphatidylinositol-3,4,5-Trisphosphate–Dependent Rac Exchanger 1 in Platelet Secretion and Aggregation
Objective: Recent studies have shown a role for Rac1 in regulating platelet functions, but how Rac1 is activated in platelets remains unclear. Phosphatidylinositol-3,4,5-trisphosphate–dependent Rac exchanger 1 (P-Rex1) was originally identified in neutrophils that regulates phagocyte functions. We sought to examine..
Advert for Healthcare Professionals only